Bluebird Bio announced Tuesday morning that it has hired Joseph Vittiglio, JD to serve as chief business and legal officer.

Vittiglio is a longtime biotech industry veteran, most recently working at Finch Therapeutics Group as chief business and legal officer. In that role, Vittiglio led the company to an initial public offering in 2021, which raised more than $131 million. 

Prior to that position, he served as general counsel and chief business officer at AMAG Pharmaceuticals, overseeing the company’s legal and business development initiatives.

“Joe’s appointment, including his decades of legal and business development expertise in biotechnology and across the life sciences industry, solidifies and strengthens our management team as we continue our transition into a commercial stage company,” Bluebird Bio CEO Andrew Obenshain said in a statement. “Joe also brings deep appreciation for bluebird’s unique culture and shares our commitment to bringing transformational therapies to patients with genetic diseases and their families. We are excited to welcome him to the flock.”

Vittiglio’s appointment is the latest development for Bluebird, which has been in the news recently for its gene therapies and their proposed prices.

At the end of last month, the Food and Drug Administration lifted a clinical hold on Bluebird’s lovo-cel, a gene therapy aimed at treating sickle cell disease. The FDA previously paused trials and enrollment for one year after a patient developed persistent anemia. 

Shortly before the hold was lifted, Bluebird released updated data from a Phase 1/2 study of lovo-cel at the American Society of Hematology annual meeting. The data eased safety concerns about two subjects in the sickle cell disease trial. The company is now targeting a regulatory filing for lovo-cel in the early part of this year. 

If approved, it would be the third Bluebird gene therapy to get a green light from the FDA, behind Skysona for CALD and Zynteglo for TDT, which both got approved in 2022.

The cost of these gene therapies has been another conversation altogether, as Bluebird priced a one-time treatment of Zynteglo at $2.8 million per infusion, while Skysona has a wholesale acquisition price of $3 million.